

# Ortho-R Abstract Accepted for Presentation at 39th SICOT Orthopaedic World Congress

KIRKLAND, QC, June 7, 2018 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (**CSE: ORTH**) ("**Ortho RTi**" or the "**Corporation**") an emerging Orthopaedic and Sports Medicine Technology company, today announced that an abstract entitled "Freeze-Dried Chitosan Solubilized in Platelet-Rich Plasma [Ortho-R] in a Sheep Model of Rotator Cuff Repair" has been accepted for e-Poster presentation at the 39<sup>th</sup> International Society of Orthopaedic Surgery and Traumatology ("SICOT") Orthopaedic World Congress, to be held in Montreal, Canada, from October 10-13, 2018.

The abstract reports on a pilot study conducted by researchers at Montreal's prestigious École Polytechnique using MRI assessment, clinical pathology and histopathology to assess residency and safety of Ortho-R and compare its efficacy versus standard of care in a pre-clinical rotator cuff injury model in sheep.

Held annually since its inception in 1929, the SICOT Orthopaedic World Congress attracts up to 3,000 delegates made up of leading surgeons, clinicians and researchers from around the globe.

"We are excited to share data from this Ortho-R pilot study at this very prestigious meeting," commented Ortho RTi's Executive Chairman and CEO, Dr. Brent Norton. "Our talented R&D team continues to break new ground in the development of Ortho-R technology, and we were excited to have this opportunity to present their progress to an international audience of surgeons and scientists."

## About Rotator Cuff Injury

The rotator cuff is the name given to the collection of four tendons that stabilize the shoulder joint. The tendons around the joint can suffer tears as a result of injury to the tendon or as a result of degeneration over time. Repetitive overhead activity, including weight lifting is often associated with cuff tears. Symptoms include a dull, aching pain, and patients often suffer secondary symptoms including a lack of sleep and weakness in the arms resulting from a lack of exercise. If conservative therapy (for example, painkillers and physical rehabilitation) is not successful, surgery will often be performed. The principle aim of surgical intervention is to reattach the torn tendon to the bone. The standard of care involves the use of suture anchors placed into the bone and the tendon being then held in place with sutures.

## About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at [www.orthorti.com](http://www.orthorti.com).

## Forward-Looking Statements

*This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are*

*founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.*

SOURCE Ortho Regenerative Technologies Inc.

View original content with multimedia:

<http://www.newswire.ca/en/releases/archive/June2018/07/c7281.html>

%SEDAR: 00037950E

**For further information:** Stephen Kilmer, Investor & Media Relations, 647.872.4849, [kilmer@orthorti.com](mailto:kilmer@orthorti.com)

CO: Ortho Regenerative Technologies Inc.

CNW 09:00e 07-JUN-18